美國居民不適用 XM 服務。
A
A

Amphenol

交易方向

交易者脈動

技術摘要

小時

財經新聞

U.S. Edwards Lifesciences, National Bank Holdings, Sage Therapeutics

U.S. RESEARCH ROUNDUP-Edwards Lifesciences, National Bank Holdings, Sage Therapeutics July 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Edwards Lifesciences, National Bank Holdings and Sage Therapeutics, on Thursday. HIGHLIGHTS * Edwards Lifesciences Corp EW.N : JP Morgan cuts to neutral from overweight * National Bank Holdings Corp NBHC.N : Piper Sandler cuts to neutral from overweight * Sage Therapeutics Inc S
A
A
C
C
G
S
C
E
H
I
A
A
E
L

Amphenol sees third-quarter revenue below estimates on weak equipment demand

UPDATE 1-Amphenol sees third-quarter revenue below estimates on weak equipment demand Rewrites throughout July 24 (Reuters) - Electronic equipment maker Amphenol APH.N forecast third-quarter revenue below market estimates on Wednesday, as customers across broadband and industrial markets scale back on spending in the face of high borrowing costs. Shares of the Wallingford, Connecticut-based company fell 4.2% in early trading.
A

Amphenol beats Q2 revenue on steady demand for defense, communication equipment

Amphenol beats Q2 revenue on steady demand for defense, communication equipment July 24 (Reuters) - Electronic equipment maker Amphenol APH.N beat market estimates for second-quarter sales on Wednesday, on the back of growing demand for defense and communication equipment. Amid the dynamic geopolitical environment, countries across the globe are expanding their investments in next-generation defense technologies.
A

Amphenol Q2 Sales USD 3,609.7 Million Vs. IBES Estimate USD 3,390 Million

BRIEF-Amphenol Q2 Sales USD 3,609.7 Million Vs. IBES Estimate USD 3,390 Million Jul 24 (Reuters) - Amphenol Q2 operating income USD 698.8 million. Q2 gross profit USD 1,213.1 million Q2 net income USD 528.7 million Q2 EPS USD 0.41 Q2 adjusted EPS USD 0.44 outlook Q3 adjusted EPS USD 0.43-0.45 outlook Q3 revenue USD 3,700-3,800 million
A

U.S. Colgate-Palmolive, McKesson, Microsoft

U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft July 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Colgate-Palmolive, McKesson and Microsoft, on Tuesday. HIGHLIGHTS * Colgate-Palmolive Co CL.N : TD Cowen initiates coverage with buy rating; PT $110 * DR Horton Inc DHI.N : JP Morgan raises target price to $180 from $163 * IQVIA Holdings Inc IQV.N : Baird raises target price to $251 from $235 * McKesso
C
H
M
M
T
V
Z
F
A
M
A
C
C
D
I

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明